Sort
4,870 grants matching “glp 1”
PET Imaging of Damaging Neuroinflammation in Alzheimer's Disease
$1,154,734Andrew Christian Larson · Einsenca Inc. · R44 · FY2023 · AG
Peroxynitrite decomposition catalyst for bowel disease
$1,152,230Inotek Pharmaceuticals Corporation · R44 · FY2002 · DK
IND-Enabling Pre-Clinical Studies to Accelerate the Clinical Development of a Humanized Anti-Cocaine Monoclonal Antibody
$1,151,637Andrew B Norman · University Of Cincinnati · U01 · FY2020 · DA
Neuroprotective And Neurorestorative Signaling Mechanisms
$1,150,803Mark P Mattson · National Institute On Aging · Z01 · FY2008 · AG
Development of small molecule therapeutics targeting AR-V7 for prostate cancer
$1,150,471Cheuk Man Cherie Au · Arma Bio, Inc. · R44 · FY2025 · CA
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens
$1,149,999Terry L Bowlin · Microbiotix, Inc · U01 · FY2009 · AI
Manganese Based MRI Contrast Agent - First In Human Clinical Trial
$1,149,940Vera Hoffman · Reveal Pharma · R44 · FY2021 · CA
Novel Antiangiogenic Peptides for Treatment of Exudative AMD
$1,148,492Nader Sheibani · University Of Wisconsin-Madison · R24 · FY2015 · EY
Antibody immunotherapeutics for biodefense against Lassa virus
$1,148,492Robert F Garry · Tulane University Of Louisiana · R01 · FY2017 · AI
Project 5: IND-enabling Critical Path Project: GMP Manufacture of a Combination I
$1,146,349John A Moss · Oak Crest Institute Of Science · U19 · FY2016 · AI
Development of Tumor and Immuno-Metabolism Based Small Molecule Therapeutics for Refractory Breast Cancer
$1,145,470Vincent Sandanayaka · Nirogyone Therapeutics, Llc · R44 · FY2020 · CA
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
$1,145,064Lloyd M Yu · Planet Biotechnology, Inc. · R01 · FY2013 · AI
Core C - The University of Texas Medical Branch at Galveston
$1,144,444Thomas William Geisbert · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2021 · AI
Role of Oral vs Injectable Glucagon Suppressors
$1,144,210Rubina A Heptulla · Albert Einstein College Of Medicine · DP3 · FY2013 · DK
LcrV Plague Vaccine with Altered Immune Modulatory Properties
$1,143,017Olaf Schneewind · University Of Chicago · U01 · FY2006 · AI
First-in-Class Macrocyclic Peptide Therapeutic For Rheumatoid Arthritis
$1,142,534Dat Quang Tran · Oryn Therapeutics, Llc · R44 · FY2015 · AR
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
$1,142,038David S Perlin · Hackensack University Medical Center · R01 · FY2022 · AI
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
$1,142,038David S Perlin · Hackensack University Medical Center · R01 · FY2023 · AI
Preclinical Alzheimers Disease Drug Development of Novel MAPK Inhibitors
$1,141,669D. Martin Watterson · Northwestern University At Chicago · U01 · FY2014 · AG
Mild Hypothermia Catheter for Reperfusion Injury
$1,140,998Terry Hubbard · 3dt Holdings, Llc · R44 · FY2018 · HL
A Study of the Function of Hormones Present in Taste Buds
$1,140,702Chee W Chia · National Institute On Aging · ZIA · FY2016 · AG
Advancing a Glioma Immunotherapy
$1,139,204Dwaine Franklin Emerich · In Cytu, Inc. · R44 · FY2014 · NS
Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy
$1,138,144Kathrin Meyer · Research Inst Nationwide Children'S Hosp · U01 · FY2015 · NS
Optimizing Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Malaria
$1,137,983Ian Cyril Bathurst · Medicines For Malaria Venture · U01 · FY2010 · AI
Treatment of pulmonary fibrosis with inhibitors of integrin alphavbeta1.
$1,137,523Dean Sheppard · University Of California, San Francisco · UH2 · FY2014 · HL